Evidence map›Paper›PMID 28575542›Full record

ArticleArthritis care & research2018

Rheumatoid Arthritis Patients' Motivations for Accepting or Resisting Disease-Modifying Antirheumatic Drug Treatment Regimens.

Yomei Shaw, Ilinca D Metes, Kaleb Michaud, Julie M Donohue, Mark S Roberts, Marc C Levesque, Judy C Chang

Abstract read
In one paragraph

Article in Arthritis care & research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Realizing the Potential of the Patient Perspective.Patient preference and adherence · 2020
    Article
  9. Challenges in Implementing Treat-to-Target Strategies in Rheumatology.Rheumatic diseases clinics of North America · 2019
    Review
  10. Observational
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Yomei ShawUniversity of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania.
Ilinca D MetesUniversity of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania.
Kaleb MichaudUniversity of Nebraska Medical Center, Omaha, and National Data Bank for Rheumatic Diseases, Wichita, Kansas.
Julie M DonohueUniversity of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania.
Mark S RobertsUniversity of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania.
Marc C LevesqueAbbVie, Worcester, Massachusetts.
Judy C ChangUniversity of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
University of Pittsburgh · USAbbVie (United States) · USThe National Databank for Rheumatic Diseases · US

Funding

Randomized observation study of biologic therapy for rheumatoid arthritisRC2AR058989 · NIAMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEVESQUE, MARC C., MORELAND, LARRY W · 2009 to 2010
$2.9M
NIAMS NIH HHS RC2 AR058989
6 · The paper itself

Abstract

objectivePatient refusal of and nonadherence to treatment with disease-modifying antirheumatic drugs (DMARDs) can adversely affect disease outcomes in rheumatoid arthritis (RA). This qualitative study describes how RA patients' feelings in response to experiences and information affected their decisions to accept (agree to adopt, initiate, and implement) or resist (refuse, avoid, and discontinue) DMARD treatment regimens.

methodsA total of 48 RA patients were interviewed about their experiences making decisions about DMARDs. The interviews were transcribed, coded, and analyzed for themes related to their internal motivations for accepting or resisting treatment regimens, using a narrative analysis approach.

resultsIn addition to feelings about the necessity and dangers of medications, patients' feelings towards their identity as an ill person, the act of taking medication, and the decision process itself were important drivers of patient's decisions. For patients' motivations to accept treatment regimens, 2 themes emerged: a desire to return to a normal life, and fear of future disability due to RA. For motivations to resist treatment regimens, 5 themes emerged: fear of medications, maintaining control over health, denial of sick identity, disappointment with treatment, and feeling overwhelmed by the cognitive burden of deciding.

conclusionFeelings in response to experiences and information played a major role in how patients weighed the benefits and costs of treatment options, suggesting that addressing patients' feelings may be important when rheumatologists counsel about therapeutic options. Further research is needed to learn how best to address patients' feelings throughout the treatment decision-making process.

Indexed as

Health Knowledge, Attitudes, PracticeMedication AdherenceMotivationTreatment RefusalAntirheumatic AgentsArthritis, RheumatoidChoice BehaviorFearHumansInterviews as TopicPatient SatisfactionRisk FactorsAntirheumatic Agents

Identifiers

PMID28575542
PMCPMC5712284
OpenAlexW2621105543

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.